SCHEMBL2173413

SCHEMBL2173413

CCc1cc(NC(=O)Cc2ccc(O)cc2OC)n[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.62
FLT3 P36888 4/20 0.62
KDR P35968 4/20 0.62
CSF1R P07333 3/20 0.61
CDK2 P24941 3/20 0.46
CCNA2 P20248 1/20 0.46
CCNA1 P78396 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
GRK6 P43250 3/20 0.41
CDK9 P50750 2/20 0.41
CDK5 Q00535 2/20 0.41
CCNT1 O60563 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK5R1 Q15078 1/20 0.41
AURKA O14965 2/20 0.40
IGF1R P08069 2/20 0.40
NPY5R Q15761 1/20 0.40
DAPK3 O43293 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175521 0.83 PDGFRB (0.63) PDGFRBFLT3KDRCSF1RALDH1A1
SCHEMBL5592064 0.79 MET (0.47) PDGFRBFLT3KDRCSF1RKDM4E
SCHEMBL4371203 0.73 KDM4E (0.51) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2174470 0.73 PDGFRB (0.82) PDGFRBFLT3KDRCSF1RMET
SCHEMBL2174542 0.73 PDGFRB (0.84) PDGFRBFLT3KDRCSF1RMET
SCHEMBL29659544 0.73 CCNA2 (0.58) PDGFRBFLT3KDRCSF1RCDK2
SCHEMBL1097868 0.72 FLT4 (0.52) PDGFRBFLT3CSF1RKDM4EALDH1A1
SCHEMBL8296534 0.71 MAOB (0.57) MEN1KMT2AMAPT
SCHEMBL2173834 0.70 EGFR (0.51) KDM4EALDH1A1HSD17B10MEN1KMT2A
SCHEMBL30581779 0.70 EGFR (0.51) KDM4EALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed
WO-2007113548-A1 NAPHTHYRIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-10-11 WO disclosed
WO-2007113565-A1 NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 PDGFRB 2155/4885FLT3 251/4885KDR 2277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.